Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to Know

This royalty-focused biotech with a broad drug portfolio reported a notable insider sale amid strong stock performance.

Ligand Advances Strategic Growth with Expanded and Strengthened Business Development Team

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has appointed two leading healthcare investors, Peter Renehan, MD, and Lee Brown as Vice Presidents of Investments and Business ...

CLO Sells LGND 5,000 Shares for $1.0 Million

Ligand Pharmaceuticals, a leader in drug licensing and royalties, reported a notable insider sale amid strong recent share ...

Ligand Pharmaceuticals: Reliable Midcap Pharma With Perfected High Growth Business Model

Ligand Pharma (LGND) outperforms via a high-margin royalty model and disciplined investing. Click here to read my most recent ...

Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says

Bank of America has initiated coverage of Ligand Pharmaceuticals Inc (NASDAQ:LGND) with a Buy rating and a $244 price target, ...

Ligand Pharmaceuticals (LGND) Is Up 7.8% After Swing to Profit and New ATM Offering Filed – Has The Bull Case Changed?

In late February 2026, Ligand Pharmaceuticals reported past fourth-quarter 2025 revenue of US$59.67 million and full-year ...

How The Ligand Pharmaceuticals (LGND) Story Is Shifting Around QTORIN And Royalty Growth

The fair value estimate for Ligand Pharmaceuticals has been nudged higher, moving from US$243.44 to US$244.56 in the latest analyst update. That shift is closely tied to refreshed views on QTORIN and ...
Seeking Alpha

Ligand Pharmaceuticals: The New Ligand Is Looking Good

The article discusses the recent developments and transformation of Ligand Pharmaceuticals. It follows up on a previous article from 12/2022 titled "A New Ligand Is Taking Shape". The focus is on the ...